Cargando…

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer

BACKGROUND: Bone-targeting agents (BTAs), such as bisphosphonates and denosumab, have demonstrated no discernable effects on tumour response or disease free/overall survival in patients with bone metastases from breast cancer. Doxycycline is both osteotropic and has anti-cancer effects. When combine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Addison, C.L., Simos, D., Wang, Z., Pond, G., Smith, S., Robertson, S., Mazzarello, S., Singh, G., Vandermeer, L., Fernandes, R., Iyengar, A., Verma, S., Clemons, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154696/ https://www.ncbi.nlm.nih.gov/pubmed/28008379 http://dx.doi.org/10.1016/j.jbo.2016.06.003

Ejemplares similares

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
por: Zhao, Huijun, et al.
Publicado: (2023)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
por: Simos, Demetrios, et al.
Publicado: (2013)

A national portfolio of bone oncology trials—The Canadian experience in 2012
por: Kuchuk, I., et al.
Publicado: (2012)

Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients
por: Beltran-Bless, A., et al.
Publicado: (2021)

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events
por: Addison, Christina L., et al.
Publicado: (2014)

Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions
por: Ibrahim, Mohammed F.K., et al.
Publicado: (2016)

Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists
por: Kuchuk, Iryna, et al.
Publicado: (2013)

Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer
por: Arnaout, Angel, et al.
Publicado: (2015)

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
por: Addison, Christina L., et al.
Publicado: (2015)

Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer
por: Simos, Demetrios, et al.
Publicado: (2014)

Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients–preliminary results
por: Fralick, M., et al.
Publicado: (2012)

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
por: Hutton, Brian, et al.
Publicado: (2013)

Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
por: Kuchuk, I., et al.
Publicado: (2013)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

P291 Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers
por: Beltran-Bless, A.-A., et al.
Publicado: (2023)

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey
por: Hutton, Brian, et al.
Publicado: (2013)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS)
por: Fernandes, Ricardo, et al.
Publicado: (2016)

Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting
por: Zhu, Xiaofu, et al.
Publicado: (2014)

Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience
por: Cole, Katherine Marie, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
por: Tu, Megan M., et al.
Publicado: (2021)

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer
por: Dent, Susan, et al.
Publicado: (2021)

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer
por: Awan, Arif, et al.
Publicado: (2020)

Effect of doxycycline and doxycycline with carica papaya on thrombocytopenia and leucopenia in acute dengue fever patients
por: Pambhar, Vivek, et al.
Publicado: (2022)

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer
por: Hutton, Brian, et al.
Publicado: (2013)

Incidence and consequences of bone metastases in lung cancer patients
por: Kuchuk, Michael, et al.
Publicado: (2013)

Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers
por: Kuchuk, Iryna, et al.
Publicado: (2013)

Doxycycline induces bone repair and changes in Wnt signalling
por: Gomes, Kátia do Nascimento, et al.
Publicado: (2017)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer
por: Fernandes, Ricardo, et al.
Publicado: (2023)

Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth
por: Kreps, Lauren M., et al.
Publicado: (2021)

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Novel Antioxidant Properties of Doxycycline
por: Clemens, Dahn L., et al.
Publicado: (2018)

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021)

Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?
por: Wong, Emily C.L., et al.
Publicado: (2019)

Doxycycline and Zinc Loaded Silica-Nanofibrous Polymers as Biomaterials for Bone Regeneration
por: Toledano, Manuel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b05j8kbbl81kuebjijgrmd3jnd